Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra
about
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@ast
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@en
type
label
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@ast
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@en
prefLabel
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@ast
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@en
P2093
P2860
P50
P356
P1476
Efficacy and safety of once-da ...... a 48 week, non-comparative, ra
@en
P2093
Aida Benalycherif
Anne-Geneviève Marcelin
Assia Samri
Claudine Duvivier
Gilles Pialoux
IMEA 040 DATA Study Group
Lambert Assoumou
Laurence Slama
Nadia Valin
Pierre-Marie Girard
P2860
P304
P356
10.1093/JAC/DKW103
P407
P577
2016-04-10T00:00:00Z